Long-term Prognosis of Pure and Impure Tachycardiomyopathy: A Reversible Form of Heart Failure

Strategic Insights -

A recent study on heart disorders and diseases - heart failure has shed light on the long-term prognosis of pure and impure tachycardiomyopathy (TCM), a reversible form of heart failure driven by arrhythmias. The research, conducted by a team of researchers at Marche Polytechnic University, aimed to examine the prognosis of pure and impure TCM against other causes of heart failure with reduced ejection fraction (HFrEF). The study analyzed data from 456 patients hospitalized with de novo, acute decompensated HFrEF, classified into four groups: pure TCM, impure TCM, ischemic HF, and non-ischaemic HF.

Key Takeaways:

  • The study found that pure TCM had the highest survival rate, with 78.2% of patients surviving over a median follow-up period of 3 years.
  • Impure TCM had a significantly lower survival rate, with 64.8% of patients surviving over the same period.
  • Ischemic HF had the lowest survival rate, with 58.5% of patients surviving over the 3-year follow-up period.
  • Sensitivity analyses using propensity score matching between the four groups revealed that pure TCM had the highest survival rate, while ischemic HF had the lowest.
  • The study concluded that an initial rhythm control strategy appears to be associated with an increased survival rate, highlighting the importance of early recognition of arrhythmias as a culprit of heart failure worsening.
  • The research involved a prospective, monocentric, observational study of 456 patients hospitalized with de novo, acute decompensated HFrEF.
  • The primary endpoint was all-cause mortality, while the secondary endpoint was the incidence of unplanned cardiovascular hospitalizations.
  • The study used propensity score matching to comparison between the four groups, providing a robust analysis of the prognosis of TCM.

Statistics:

  • 78.2% of patients with pure TCM survived over a median follow-up period of 3 years.
  • 64.8% of patients with impure TCM survived over the same period.
  • 73.4% of patients with non-ischaemic HF survived over the 3-year follow-up period.
  • 58.5% of patients with ischemic HF survived over the 3-year follow-up period.
  • 3 years was the median follow-up period used in the study.
  • 1.5-5.1 years was the interquartile range for the follow-up period.
  • A total of 456 patients were included in the study.
  • 4 groups were analyzed in the study: pure TCM, impure TCM, ischemic HF, and non-ischaemic HF.

Sources:

  • Long-term prognosis of pure and impure tachycardiomyopathy. ESC Heart Failure, 2025.
  • NewsRx. Researchers at Marche Polytechnic University Describe Findings in Heart Failure (Long-term prognosis of pure and impure tachycardiomyopathy). Health & Medicine Week. October 24, 2025; p 5780.